Samsung Bioepis announced Wednesday that its first antibody-drug conjugate (ADC) candidate, SBE303, has been granted Fast Track designation by the US Food and Drug Administration (FDA). SBE303 targets Nectin-4, a protein overexpressed on tumor cells, and is being developed to treat patients with locally advanced or metastatic urothelial cancer who have previously received Nectin-4-targeted therapy.